Impact of an HIV budget crisis – modelling HIV infections and mortality in 26 countries

Authors: Debra ten Brink MD[1], Rowan Martin-Hughes PhD[1], Anna Bowring PhD[1], Nisaa Wulan MPH[1], Kelvin Burke MSc[1], Tom Tidhar MSc[1], Shona Dalal PhD[2], Nick Scott PhD[1]

[1]Burnet Institute, Melbourne, Australia

[2]Department of Global HIV, Hepatitis and STIs Programmes, World Health Organization, Geneva, Switzerland

Corresponding author: Debra ten Brink, debra.tenbrink@gmail.com, +31619888412

Keywords: HIV financing, international funding, mathematical modelling, key populations

Summary

Background: International funding for HIV has been critical in reducing new HIV transmissions and deaths. Five countries that account for over 90% of international HIV funding announced reductions in international aid of 10%-70% (20% weighted average) commencing in 2026, and immediate cessation of foreign aid was issued by the US government on 20 January 2025. We investigated the potential impact of these funding reductions on HIV incidence and mortality in 26 countries through mathematical modelling.

Methods: We used 26 existing, country-validated Optima HIV models (Albania, Armenia, Azerbaijan, Belarus, Bhutan, Cambodia, Colombia, Costa Rica, Cote d'Ivoire, Dominican Republic, Eswatini, Georgia, Kazakhstan, Kenya, Kyrgyzstan, Malawi, Malaysia, Moldova, Mongolia, Mozambique, South Africa, Sri Lanka, Tajikistan, Uganda, Uzbekistan, Zimbabwe). HIV incidence and HIV-related deaths were projected across 2025-2030 for scenarios with: most recent HIV spending continued (status-quo); anticipated international aid reductions for HIV prevention and testing from five major donor countries; and anticipated international aid reductions plus discontinued President's Emergency Fund for AIDS Relief (PEPFAR) support for treatment and facility-based testing. Upper and lower bounds reflected different assumptions about mitigation and absorption of funding reductions. Country-specific impacts were based on the proportion of international and PEPFAR funding received.

Findings: Across the 26 countries, the 20% reduction in international aid resulted in an 11%-71% reduction in HIV prevention and testing spending, and a cumulative additional 0.04 – 1.13 million (1·7%-54·1%) new HIV infections and 0.002 – 0.03 million (0·3%-3·9%) HIV-related deaths across 2025-2030. With PEPFAR support also discontinued, there were an additional 2·47-6·36 million (118·1%-304·8%) new HIV infections and 0·40 - 1·71 million (46·9% - 198·9%) HIV-related deaths across 2025-2030 compared with the status quo. Impacts were greatest in countries with a higher percentage of international funding, and those with increasing incidence among key populations.

Interpretation: Unmitigated reductions in international HIV funding could significantly reverse progress by 2030, disproportionately affecting key and vulnerable populations. Establishing sustainable funding mechanisms to safeguard prevention, testing, and care programs is critical to sustaining reductions in incidence and mortality.

Funding: Country models utilized in this project have been financially supported by the Gates Foundation, Global Fund to Fight AIDS, malaria and tuberculosis, UNAIDS and World Health Organization (WHO).

Background

Substantial progress in the global HIV response has largely been driven by donor financing. Many nations with a high burden of HIV depend on international funding for essential HIV prevention and testing services, while some also rely on external support for treatment provision. Donor dependency in low- and middle-income countries has remained at approximately 40% since 2015 (1). Interventions for key populations (e.g., people who inject drugs (PWID), men who have sex with men (MSM), female sex workers (FSW), trans and gender diverse people (TG), and people in prisons and other closed settings often rely on internationally-funded HIV prevention and testing programs (2, 3).

As of 2023, five major donors provided over 90% of total international HIV funding – the United States (US) (73%), United Kingdom (UK) (9%), France (4%), Germany (3%), and the Netherlands (2%) (4). However, near the end of 2024, four of these five countries announced significant cuts to foreign aid, with one instituting a budget freeze. Our calculations estimate that the weighted average of announced cuts represent a 4·4% reduction in total global international HIV funding in 2025 and a further 15·6% (totalling 20%) in 2026 (5-8). The US has historically provided the largest financial share of the global HIV response, with 92% of US contributions being delivered bilaterally through the US President's Emergency Plan for AIDS Relief (PEPFAR). Consequently, the immediate cessation of PEPFAR support issued by the US government on 20 January 2025, with a 90-day review period, has the potential to profoundly disrupt the global HIV response. Its most immediate effect has been on the HIV health workforce – thereby undermining HIV prevention, testing, and treatment efforts, even in settings where domestic budgets support consumables (9). Although a humanitarian waiver ostensibly protects life-saving interventions, including antiretroviral therapy (ART), pervasive uncertainty around its scope has led to continued disruptions (10, 11). Equally concerning is the absence of clarity on how funding might be affected following the 90-day period, highlighting the need to prepare for scenarios where PEPFAR resources are abruptly withdrawn (10, 12).

Model-based analyses consistently demonstrate that underinvestment in HIV prevention leads to increased incidence and mortality, which, in turn, drive future treatment costs and strain domestic health financing (13). Recent rapid evaluations have estimated the specific impact of discontinued PEPFAR support. For instance, amfAR projected that 220,000 people across 54 PEPFAR-supported countries could lose daily access to antiretroviral therapy (ART) (14), while one PEPFAR impact tracker indicated 39,272 adult deaths could occur over the 90-day period, and UNAIDS estimated 3,103 new adult HIV infections between 21 January and 13 February 2025 (15, 16). Tram et al. estimated over 100,000 HIV-related deaths could occur in 21 PEPFAR-supported countries during the 90-day pause (17).

During the COVID-19 pandemic, Jewell et al. similarly reported that a six-month ART service interruption in sub-Saharan Africa was associated with a 1.63-fold increase in HIV-related deaths within one year (18). Although the projected consequences of the 2025 US funding cessation are substantial, the broader risk of dwindling international support extends beyond PEPFAR-funded countries, as other donors may also re-prioritize or reduce aid. We

sought to evaluate the potential impact of sustained cuts over a five-year period from all major international donors on the HIV epidemic across 26 existing country models.

Methodology

Model overview

The Optima HIV model was used for this analysis (19). In brief, Optima HIV is a dynamic compartmental model of HIV transmission, disease progression and care cascade progression that includes setting-specific population disaggregation (by age, sex and risk factors). The epidemic model is overlaid with a set of programs that can impact parameters when their coverage is varied, and an economic framework that links spending on programs to program coverage.

Settings

We used existing calibrated Optima HIV models for 26 countries (Albania, Armenia, Azerbaijan, Belarus, Bhutan, Cambodia, Colombia, Cote d'Ivoire, Eswatini, Georgia, Kazakhstan, Kenya, Kyrgyzstan, Malawi, Malaysia, Moldova, Mongolia, Mozambique, South Africa, Sri Lanka, Tajikistan, Uganda, Uzbekistan, Zimbabwe) that were established and validated by country teams between 2022 and 2024 (20). These countries represent approximately 42% of estimated people living with HIV and 25% of new HIV infections globally according to 2024 UNAIDS estimates (21).

HIV funding sources

Targeted HIV prevention and testing spending was available in each country-validated model disaggregated by intervention. However, for this analysis financing sources also needed to be obtained, and financial data were collated from the existing Global AIDS monitoring (GAM)/GARPR database, accessed through the UNAIDS Financial Dashboard (1), which disaggregates total spending by domestic (private and public), PEPFAR, Global Fund, and other international spending. Due to missing GAM data, Cote d'Ivoire PEPFAR spending was drawn from the Country and Regional Operational Plan (COP) 2022 (22).

Scenarios

A total of five scenarios were modelled, based on potential cuts to overall international aid, discontinuation of PEPFAR, and potential mitigation efforts (Table 1). Scenarios were assessed over the period 2025-2030 and 2025-2050. Scenario 1 (status-quo) was based on a continuation of the most recently reported national HIV spending on prevention and testing in each country, and continued proportion of people living with HIV who are diagnosed and retained in care on ART. Facility-based testing and treatment were expected to continue to be funded domestically.

Scenarios 2 and 3 were based on the impact of the announced reductions in international aid as of 10 January 2025, and differentiated as a lower and upper bound for the potential impact depending on how countries compensate for these reduced funds. It was assumed that the announced 4.4% funding cuts in 2025 and 20.0% funding cuts in 2026 (Table A 1) would affect each country's international funding equally (i.e. the 20.0% reduction in international HIV funding applied to each country's international sources, including PEPFAR). Scenario 2 gives a lower bound on impact by assuming each HIV prevention, testing, and treatment support interventions (referred to as HIV prevention and testing hereafter), excluding facility-based testing and treatment, would individually experience a proportional 4·4% and 20.0% reduction in international spending in 2025 and 2026 (onwards) respectively. This includes condom programs, community-based testing, HIV self-testing, HIV prevention and testing for key populations (disaggregated by programs for migrants, FSW, MSM, PWID, and TGW), needle syringe exchange programs, linkage to care programs, viral load monitoring, retention to care, oral and long-acting pre-exposure prophylaxis (PrEP), and voluntary medical male circumcision (VMMC). Scenario 3 gives an upper bound on impact without HIV treatment being affected, by assuming the dollar value of all PEPFAR-supported HIV spending plus 20% of other international funding would be taken from HIV prevention and testing, to a minimum of zero spending, after which it was assumed any remaining shortfall necessary to continue HIV treatment coverage would be met by additional domestic spending or reallocated international spending (i.e. countries maintain treatment coverage by taking all reductions from prevention and testing). These reductions were modelled to continue for the remainder of the projection period.

Scenarios 4 and 5 were modelled around the discontinuation of PEPFAR funding for all PEPFAR-supported countries, differentiated as a lower and upper bound for the potential impact depending on whether mitigation occurs or not. Both lower and upper bound scenarios included the announced reductions in international aid from Scenario 2 (4.4% in 2025 and 20% in 2026). Scenario 4 gives a lower bound on impact, by assuming facility-based testing would remain undisrupted, but HIV treatment coverage (the proportion diagnosed on treatment as well as proportion of pregnant women with HIV receiving HIV services to prevent vertical transmission) would reduce in each country by the proportion of PEPFAR funding divided by total HIV funding due to immediate discontinuation of funding. This scenario assumed mitigation with new funding sources could result in HIV treatment coverage lost as a result of PEPFAR discontinuation returning to 75% of 2024 levels within 12 months, and 100% of 2024 levels with 24 months.

Scenario 5 modelled a worst-case disruption and gives an upper bound on impact of immediate PEPFAR discontinuation. In countries with more than 20% of total HIV spending from PEPFAR, this scenario assumed HIV treatment coverage and facility-based testing would both temporarily reduce to zero as a result of health system disruptions due to reported widespread layoffs of the health workforce (with some continuation of treatment as a result of multi-month dispensing). Treatment coverage was assumed to linearly increase by 2030 to status quo levels, multiplied by non-PEPFAR funding divided by total HIV funding (the initial disruption in Scenario 4), and facility-based testing linearly recovering to status quo

levels within 12 months. In countries with lower proportions of PEPFAR support, initial changes in coverage were assumed to be the same as Scenario 4, but with no recovery of treatment coverage.

Table 1. Modelled scenarios

	Description
Scenario 1 (Status quo)	Fixed HIV spending for HIV prevention and testing programs continued from 2025-2030.[1]
Scenario 2 (Proportional cuts)	For each country, the proportion of international funding a country receives in future years relative to 2024 is reduced by 4·4% in 2025 and a further 15·6% (total 20%) in 2026, and maintained at the 2026 level in all years after 2026.[1] Across 26 countries, assumes efficiencies or domestic financing absorbs 87% of the anticipated cuts to maintain treatment, facility-based testing, and health systems.
Scenario 3 (Reallocated prevention budget to treatment)	Assumed the dollar value of all PEPFAR-supported HIV spending plus 20% of other international funding would be taken from HIV prevention and testing spending, to a minimum of zero spending, after which it was assumed any remaining shortfall necessary to continue HIV treatment coverage would be met by additional domestic spending or reallocated international spending. This 'worse case' scenario captures the risk of reallocation both within and between countries to maintain treatment from 2026 to 2030.[1] Across 26 countries, assumes efficiencies or domestic financing absorbs 16% of the anticipated cuts to maintain treatment, facility-based testing, and health systems.
Scenario 4 (Discontinued PEPFAR support with mitigation)	In addition to longer-term cuts in Scenario 2, immediate cessation of all PEPFAR funding in a given country budget from 20 January 2025 to 2030, but assuming linear return to treatment to 75% of 2024 levels within 12 months, and 100% of 2024 levels with 24 months.
Scenario 5 (Discontinued PEPFAR support with no mitigation)	In addition to longer-term cuts in Scenario 2, immediate cessation of all PEPFAR funding in a given country budget from 20 January 2025 to 2030. This captures the immediate disruption of unknown duration, and the potential for wider health systems impacts in countries with more than 20% of total HIV spending from PEPFAR (8 modelled countries in SSA).

[1]2024 coverage of HIV treatment maintained as a proportion of diagnosed people living with HIV. 2024 spending on facility-based testing including antenatal clinics assumed to be maintained.

Outcomes

For each scenario the model estimated new HIV infections and HIV-related deaths. Outcomes were assessed across the 26 countries, as well as by region (Asia and Pacific (APAC); Eastern Europe and Central Asia (EECA); Latin America and the Caribbean (LAC); sub-Saharan Africa (SSA)) and disaggregated by children (0-14) key population adults (15-99) and general population adults (15-99). Key populations (KP) were country-defined and included migrants, prisoners, FSW, entertainment workers, clients of FSW, MSM, PWID, and TG.

Role of the funding source

Country models utilized in this project have been financially supported by the Bill and Melinda Gates Foundation, Global Fund to Fight AIDS, malaria and tuberculosis, UNAIDS and World Health Organization (WHO).

Findings

Total HIV spending

According to 2019-2023 GAM data, international funding for total national HIV responses ranged from 0% in Tajikistan to 100% in Bhutan, Cote d'Ivoire, and Zimbabwe (Table A 2). PEPFAR funding contributed 15-66% of total national HIV funding in 12 countries: Cambodia, Colombia, Cote d'Ivoire, Kazakhstan, Kyrgyzstan, Eswatini, Kenya, Malawi, Mozambique, South Africa, Uganda and Zimbabwe (Table A 2).

For each of the 26 countries, the proportion of total HIV spending potentially subject to cuts is outlined in Figure 1 (a) (red and yellow). In each of the eight modelled SSA PEPFAR-supported countries, PEPFAR funding accounts for more than 20% of total HIV funding, and more than 60% of total HIV funding in Malawi, Mozambique, Uganda, and Zimbabwe.

Figure 1. Proportional distribution of latest reported spending potentially subject to budget cuts for 26 countries: (a) total HIV spending, and (b) spending on HIV prevention and testing interventions



(b)



Notes: APAC, Asia and Pacific; EECA, Eastern Europe and Central Asia; LAC, Latin America and the Caribbean; SSA, sub-Saharan Africa. Source: GAM 2023.

Prevention and testing spending

Spending on prevention and testing (excluding treatment and facility-based testing) in 2023 ranged from 2% (Uzbekistan) to 59% (Bhutan) of overall HIV spending in the GAM/GARPR database. The proportion of spending on prevention and testing was typically higher in smaller epidemics where less resources are required for ART.

In the 26 countries modelled, from 2019 to 2022 an average of 53% of total prevention spending was internationally supported compared with 29% of treatment spending (Figure 1 (b), Table A 3). For example, in Uzbekistan 70% of the HIV response is domestically funded and anticipated international aid reductions translate to only a 5·7% of total spending. Nevertheless, if these reductions in international aid were taken entirely came from HIV testing and prevention (to protect spending on treatment), this could result in these interventions (including services for key populations) being entirely defunded.

Impact of reduced international aid and discontinued PEPFAR support on new HIV infections and deaths

In the status quo scenario, an estimated 2,087,900 new HIV infections and 860,800 HIV-related deaths could occur from 2025 to 2030 in the 26 countries included in this analysis.

If anticipated international aid reductions were realised and sustained across 2025-2030, an additional 0·04 – 1·13 million (1·7%-54·1%) new HIV infections and 0·002 – 0·03 million (0·3%-3·9%) HIV-related deaths could occur across the 26 countries over the same six-year period, depending on how the funding cuts are absorbed by countries.

If PEPFAR support is additionally discontinued over the same period, an additional 2,47-6,36 million (118·1%-304·8%) new HIV infections and 0·40-1·71 million (46·9% - 198·9%) HIV-related deaths could occur across the 26 countries compared to the status-quo, depending on whether mitigation occurs (Figure 2). This is mainly driven by projected increases in outcomes in South Africa, Mozambique, and Uganda (Table A 4).

Impact of reduced international spending or PEPFAR support on key populations

In modelled countries within the EECA, LAC, and APAC regions, the relative increase in new HIV infections was estimated from 1.3 to 6 times higher among key and vulnerable populations than non-key populations depending on the scenario. The highest relative increase was seen in Scenario 3 (Reallocated prevention budget to treatment) which most directly impacts on key population prevention and testing without disrupting basic service availability that applies to all populations. For sub-Saharan Africa, where HIV prevention and testing spending is less focused on key populations (e.g. PrEP programs), the anticipated funding cuts may result in a higher proportional impact among the general population adults (Figure 3).

Children are disproportionately affected in EECA and SSA, with an additional 0.6 million new HIV infections from 2025-2030 in SSA (+244.7%). The status quo scenario projects 183,800 vertical transmissions and 55,600 HIV-related deaths among children aged 0-14 from 2025-2030. Over this period, vertical transmissions could increase with an additional 563,500 (+306·6%) in the unmitigated PEFPAR discontinued funding scenario, while child deaths could increase with an additional 82,100 (+147·8%) in the same scenario.

Figure 2. Anticipated additional cumulative new HIV infections and HIV-related deaths, compared with status quo, as a result of four funding cut scenarios



Notes: APAC, Asia and Pacific; EECA, Eastern Europe and Central Asia; KP, key population groups; LAC, Latin America and the Caribbean; SSA, sub-Saharan Africa.

Figure 3. Proportional increase of new HIV infections among children (0-14), general population adults (15-99) and key population adults (15-99) relative to status quo for each scenario



Notes: APAC, Asia and Pacific; EECA, Eastern Europe and Central Asia; KP, key population groups; LAC, Latin America and the Caribbean; SSA, sub-Saharan Africa. Small numbers of incidence in children in APAC resultted in disproportionate changes with status quo, these results were therefore excluded.

Impact on progress toward 2030 incidence reduction target

Across the 26 modelled countries, there has been a steady 8.3% average year-on-year decrease in new HIV infections between 2010 and 2023, leading to a cumulative 68% reduction in new HIV infections over that timeframe. With anticipated international aid reductions, the number of new infections in 2026 could rise by 0.002 – 0.18 million (7·4% - 56·3%) from 2024 levels, potentially returning to 2019 levels in the upper bound (scenario 3, with prevention budget reallocated to treatment). With PEPFAR also discontinued, the number of new infections in 2026 could rise by 0.5-1.2 million (153·2% to 363·1%) from 2024 levels depending on mitigation, potentially resulting in more new infections than estimated in any year from 2000 to 2010 across the 26 countries (Figure 4).

The status quo scenario of fixed annual spending on HIV prevention and testing while maintaining the proportion of diagnosed people living with HIV on treatment leads to a projection of steady incidence rates but slightly increasing number of new HIV infections consistent with population growth. This captures a baseline of relative impact of funding cuts especially within the short-term, but ongoing progress towards UNAIDS 2030 targets may be feasible through new efficiencies consistent with the historical trend of year-on-year reductions in new HIV infections (Figure 4, dashed line).

Figure 4. Annual new HIV infections projected from 2000 to 2050, relative to UNAIDS 2030 target for reduced new HIV infections (90% reduction from 2010 baseline). Anticipated cuts captures the range of impacts given by the proportional cuts and reallocated prevention budget to treatment scenarios (Scenario 2 and Scenario 3, red), while PEPFAR discontinued captures the range of impacts with and without mitigation (Scenario 4 and Scenario 5, purple). The dashed line shows a continuation of historical 8.3% year-on-year reductions in new HIV infections from 2023 levels.



Discussion

Discontinuation of international financial support for HIV has potential to jeopardize decades of progress in reducing the number of new HIV infections and deaths, especially in Sub-Saharan Africa. Even under optimal mitigation scenarios, stopping large-scale funding can unravel 10–15 years of progress in reducing new infections within a few years. This collapse in service provision risks reversing global gains and undermining the momentum of initiatives like the 95-95-95 targets. In the worst-case scenario, if PEPFAR funding were ceased entirely and no equivalent mechanism replaced it, surges in HIV incidence could potentially undo nearly all progress achieved since 2000. The steady and continuous historical reduction in new HIV infections from 2010 to 2023 suggests that the loss of progress through PEPFAR discontinuation could not rapidly be reversed, so even if funding were reinstated after 12-24 months, the world could remain 20-30 years behind in ending AIDS as a public health threat.

Children may be unreasonably affected, especially in SSA where disruptions could lead to more vertical transmissions, resulting in an almost 3-fold increase in new HIV infections among children. Similarly, key and vulnerable populations, particularly outside of sub-Saharan Africa, are likely to be disproportionately impacted by the potential reallocation of funds away from HIV prevention, testing, and treatment-adjacent services (23). This could result in an estimated 1.6-6-fold increase in new HIV infections compared with the general populations. While this trend was less apparent in sub-Saharan Africa where HIV transmission remains high outside of key populations, looking at absolute number of new infections rather than incidence density likely masks the true impact on key populations. Currently HIV services for key populations are more likely to be funded through international sources such as PEPFAR (1), and in many settings these groups face social and structural barriers to accessing HIV services (24). Without tailored HIV prevention and testing strategies for these populations, epidemic control is jeopardized while key populations potentially become more marginalised. In countries lacking secure domestic funding for these essential services, diminishing resources can rapidly translate into a resurgence of new infections. Given that testing is the entry point to both prevention (e.g. PrEP) and treatment (ART initiation), disruptions in the testing cascade directly lead to an increase in late HIV diagnoses and onward transmission (25).

There have been no significant global funding increases for HIV since 2017 (1), and there has been an ongoing push for countries to increasingly finance their HIV responses. One outcome of the recent global HIV financing shocks could be catalysing domestic uptake of some HIV interventions, particularly those for key populations which are majority supported by international funds. This analysis suggests that it may be possible to minimize the impact of the announced international aid reductions to a 1·7% increase in new HIV transmissions and a 0·3% increase in HIV-related deaths over 2025-2030 – provided PEPFAR support were reinstated in full and countries could significantly absorb up to 88% of financial cuts, through a combination of efficiencies and domestic financing. However, even with PEPFAR support reinstated, countries may not be able to resource HIV responses sufficiently to mitigate the anticipated gaps, given competing priorities.

These estimates likely underestimate the true impact of unmitigated funding cuts, as the modelled status quo scenario (fixed HIV prevention and testing spending at the latest reported level) remains static. This does not account continuation of historical efficiencies, such as cost reductions in antiretrovirals (20); technical efficiencies in program implementation; allocative efficiency to prioritize spending to the most cost-effective interventions (20); and highly targeted HIV prevention innovations such as PrEP (17). These efficiencies have been integral to steady declines in new HIV infections despite flat HIV global funding. In the best case scenario, these mechanics could be expected to continue leading to ongoing progress towards HIV targets, while more severe funding cuts the mechanisms themselves may be cut, and those future innovations would also be lost.

A critical aspect of maintaining continuity of HIV services and preventing a resurgence in new infections and deaths is to urgently build the capacity of national health systems to absorb the financial burden. The Head of the South African Medical Research Council echoes this, outlining the need for autonomous health systems in the global south (26). A multipronged approach can help offset the effects of sudden funding cuts and build long-term sustainability. Integrating HIV care with other primary healthcare services may improve efficiency, and leverage shared resources (27). In Vietnam, this integration along with health insurance to cover HIV services, centralizing antiretroviral procurement and mobilization of domestic resources has resulted in an increase domestic financing of the HIV response from 32% in 2013 to 52% in 2022 (28) . Introducing a modest HIV-specific tax levy or incorporating HIV services into a broader health insurance mechanism may provide additional domestic funding streams (29). Such measures, although challenging, have been successfully trialled in some sub-Saharan African countries (e.g., Zimbabwe's AIDS levy (30)). Finally Tram et al., suggest safeguarding critical services through adopting a five-year phasing out, co-financing at least 50% of the HIV response, while governments develop reliable financing channels (17).

There are several limitations in this analysis, starting with the unpredictability of the HIV fiscal space. It is unknown whether reductions in international aid will continue to escalate, whether PEPFAR will be reinstated (and to what extent), or whether a variety of mitigation efforts will be introduced. It is also unknown how countries will absorb these funding cuts. Therefore, the selected scenarios include wide ranges of potential impact reflecting this uncertainty. Secondly, there may be a mismatch between the proportion of funding that is international for each country as informed by the GAM database, and the most recent year for the utilized Optima HIV budgets. We are also aware that the GAM database may be incomplete, particularly in terms of domestic funding. Additionally, Optima HIV analyses were set up to respond to specific policy questions, and not all funded HIV interventions were modelled and subject to funding reductions in the modelled scenarios. This could result in the modelled impacts being an under-estimate of true impacts. The Optima HIV models were updated relatively recently (2022-2024), however there may be more recent epidemiological and economic data available that has not been considered. Data on potential behaviour change to mitigate HIV transmission in the case of cessation of HIV services are not available. Finally, only 26 countries were eligible for inclusion in this analysis, and regional

results may not be fully representative especially in the LAC region (3 countries) and APAC region (4 countries). In the context of the global HIV epidemic, the magnitude of assessed impact would be much larger, especially considering these countries have undergone allocative efficiency analyses. Nevertheless, these countries account for 41% of global people living with HIV, with a few countries contributing a significant burden of HIV.

Overall, most limitations are likely to result in under-estimating rather than over-estimating the real impacts of immediate and severe funding cuts to HIV programs globally, especially in the sub-Saharan African region where disruptions to the supply chain, health workforce, and overall health systems could result in much broader health impacts beyond HIV. Future research, including optimization of reduced budgets, could inform countries as to which HIV prevention, testing and treatment interventions, should be prioritized for maximum impact on their HIV epidemic.

Interpretation

The immediate cessation of US government support for HIV presents an inflection point, compelling the global health community to reassess sustainable financing strategies of the HIV response. While marginal or carefully managed funding cuts could potentially be absorbed without substantial increases in new HIV infections and deaths, an abrupt or severe funding reduction could reverse decades of gains, particularly in sub-Saharan Africa. Governments, donors, and stakeholders must collaborate on feasible mitigation strategies to preserve HIV prevention, testing, and treatment services. In doing so, the global community can secure both the immediate and long-term stability of the HIV response and protect the health systems so integral to achieving epidemic control.

Declaration of interests

All authors declare no conflict of interest.

References

1. UNAIDS. GARPR16-GAM2023 Programme Expenditures. 2025.
2. DiCarlo MC, Dallabetta GA, Akolo C, Bautista-Arredondo S, Digolo HV, Fonner VA, et al. Adequate funding of comprehensive community-based programs for key populations needed now more than ever to reach and sustain HIV targets. African Journal of Reproduction and Gynaecological Endoscopy. 2022;25(7):e25967.
3. Vannakit R, Andreeva V, Mills S, Cassell MM, Jones MA, Murphy E, et al. Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations. The Lancet HIV. 2020;7(5):e366-e72.
4. Wexler AK, J.; Oum, S., Lief, E. Donor Government Funding for HIV in Low- and Middle-Income Countries in 2023. 2024.
5. Government of the Netherlands. First development budget cuts announced: overhaul of grants for NGOs 2024 [13 January 2024]. Available from: https://www.government.nl/latest/news/2024/11/11/first-development-budget-cuts-announced-overhaul-of-grants-for-ngos.
6. Lynch C. Donald Trump won. What does that mean for development? 2024.
7. Murphy H. Devex Newswire: The two major donor countries facing billions in aid cuts. Devex Newswire. 2024.
8. Bollag B. France slashes €1B more from aid budget. Devex Newswire. 2024.
9. UNAIDS. UNAIDS urges that all essential HIV services must continue while U.S. pauses its funding for foreign aid Geneva, Switzerland2025 [Available from: https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2025/february/20250201_us-funding.
10. Yadav P. The USAID "Lifesaving" Waiver Is a Mirage Without Sufficient Staffing 2025 [Available from: https://www.thinkglobalhealth.org/article/usaid-lifesaving-waiver-mirage-without-sufficient-staffing.
11. Lankiewicz E, Sharp A, Drake P, Sherwood J, Macharia B, Ighodaro M, et al. Early impacts of the PEPFAR stop-work order: a rapid assessment. Journal of the International AIDS Society. 2025;28(2):e26423.
12. Ratevosian J, Millett G, Honermann B, Bennett S, Connor C, Bekker L-G, et al. PEPFAR under review: what's at stake for PEPFAR's future. The Lancet. 2025.
13. Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD, et al. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the Fast-Track approach. PLOS ONE. 2016;11(5):e0154893.
14. amfAR. Trump administration's order requiring immediate suspension of all HIV services provided by PEPFAR will place lives at risk.; 2025.
15. UNAIDS. Impact of recent U.S. shifts on the global HIV response 2025 [Available from: https://www.unaids.org/en/topic/PEPFAR_impact.
16. Nichols BE, Geng EH, Moakley E, Phillips AN, Imai-Eaton JW, Stover J, et al. Rapid development of an online tracker to communicate the human impact of abruptly halting PEPFAR support. Journal of the International AIDS Society. 2025;28(3):e26433.
17. Tram KH, Ratevosian J, Beyrer C. By executive order: The likely deadly consequences associated with a 90-day pause in PEPFAR funding. Journal of the International AIDS Society. 2025;28(3):e26431.
18. Jewell BL, Mudimu E, Stover J, ten Brink D, Phillips AN, Smith JA, et al. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. The Lancet HIV. 2020;7(9):e629-e40.

19. Kerr CC, Stuart RM, Gray RT, Shattock AJ, Fraser N, Benedikt C, et al. Optima: a model for HIV epidemic analysis, program prioritization, and resource optimization. Journal of Acquired Immune Deficiency Syndromes. 2015;69(3):365–76.
20. Ten Brink DC, Bowring AL, Martin-Hughes R, Wulan N, Xiao Y, Burke K, et al. Optimising HIV spending in 12 eastern European and central Asian countries: a modelling study. Lancet HIV. 2024;11(10):e690-e9.
21. UNAIDS. AIDSinfo - Global data on HIV epidemiology and response 2025 [Available from: https://aidsinfo.unaids.org/.
22. PEPFAR. Cote d'Ivoire Country Operational Plan (COP/ROP) 2022. 2022.
23. Pettifor A, Nguyen NL, Celum C, Cowan FM, Go V, Hightow-Weidman L. Tailored combination prevention packages and PrEP for young key populations. Journal of the International AIDS Society. 2015;18:19434.
24. Gesesew HA, Tesfay Gebremedhin A, Demissie TD, Kerie MW, Sudhakar M, Mwanri L. Significant association between perceived HIV related stigma and late presentation for HIV/AIDS care in low and middle-income countries: A systematic review and meta-analysis. PLoS One. 2017;12(3):e0173928.
25. Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. Aids. 2012;26(7):893-6.
26. Ntusi N. US aid cuts are an opportunity to reimagine global health. Nature Medicine. 2025.
27. Goldstein D, Salvatore M, Ferris R, Phelps BR, Minior T. Integrating global HIV services with primary health care: a key step in sustainable HIV epidemic control. The Lancet Global Health. 2023;11(7):e1120-e4.
28. Tran BX, Vu G, Latkin C. Financing for HIV/AIDS in the dual transition of epidemics and economy: the 10-year experience of Vietnam. Lancet Reg Health West Pac. 2023;38:100886.
29. World Health Organization. HIV, universal health coverage and the post-2015 development agenda: a discussion paper: World Health Organization; 2014.
30. Bhat N, Kilmarx PH, Dube F, Manenji A, Dube M, Magure T. Zimbabwe's national AIDS levy: A case study. Sahara j. 2016;13(1):1-7.